Call for Abstract

15th World Congress on Cancer Therapy, Biomarkers & Clinical Research, will be organized around the theme “Exploring the Possibilities in Shaping the Future of Biomarkers”

Biomarkers 2016 is comprised of 31 tracks and 91 sessions designed to offer comprehensive sessions that address current issues in Biomarkers 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Biomarker is a characteristic diagnostic tool that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. Biomarkers can be molecules, or genes, gene products, enzymes, or hormones referred as protein biomarkers, analytical biomarkers, blood biomarkers, fluorescent biomarkers, circulating biomarkers and molecular biomarkers to quantify the degree of disease condition. Biomarkers are the measures used to perform a clinical assessment in case of cancer biomarkers. They predict health states in individuals across populations so that appropriate therapeutic intervention can be planned. In the current scenario more than a thousand organizations and universities have contributed to the field of Biomarkers research especially molecular and cancer biomarkers, with its wings spreading across major organizations in USA, UK, Germany and China. The global biomarkers market is expected to grow from $29.3 billion in 2013 to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.Different types of biomarkers include Protein biomarkers, Fluorescent biomarkers, Blood biomarkers, Cancer biomarkers, Analytical biomarkers and Molecular Biomarkers.

  • Track 1-1Protein biomarkers
  • Track 1-2Fluorescent biomarkers
  • Track 1-3Blood biomarkers: Serum and blood cells
  • Track 1-4Analytical biomarkers
  • Track 1-5Molecular Biomarkers

Cancer biomarkers are used to detect the natural course of a tumour and are used to assess chances of developing cancer. Biomarkers in cancer screening play an important role in cancer detection and risk assessment to reduce cancer deaths. Tumour biomarkers are used to detect cancer development and progression. Uterine cervical cancer, endometrial cancer, trophoblastic neoplasms and ovarian cancer are gynaecologic malignancies for which tumour markers are in clinical use. Effective cancer biomarkers are used to reduce cancer mortality rates by facilitating diagnosis of cancers at early stages. Cancer biomarkers can also be used in diagnosis, risk assessment and recurrence of cancer.

  • Track 2-1Biomarkers in cancer screening
  • Track 2-2Tumour biomarkers
  • Track 2-3Potential cancer biomarkers
  • Track 2-4Cancer biomarkers and ethical issues
  • Track 13-1Cardiovascular disease
  • Track 13-2 neurological disorder
  • Track 13-3Rheumatic Diseases:

The branch of genomics that determines the biological function and complex association of the genes and their products depicts the functional genomics. The measurable degree of these parameters through various processes and equipment inclusive of Next generation sequencing, Personalized genome sequencing and mi-RNA sequencing utilizing cellular entities to predict SNP biomarkers, immuno fluorescent biomarkers, oxidative stress biomarkers, si-RNA and mi-RNA will aid in better understanding of the disease outcome. The cytogenetic biomarkers are a feasible diagnostic tool to detect DNA and chromatin damage. 

  • Track 14-1Next gen sequencing
  • Track 14-2Personalized genome sequencing
  • Track 14-3Micro RNA sequencing
  • Track 14-4SNP biomarkers
  • Track 14-5Immuno fluorescent biomarkers
  • Track 14-6Molecular imaging biomarkers
  • Track 14-7Oxidative Stress Biomarkers

The newly emerged discipline in the field of cytogenetic and functional genomics is Molecular imaging biomarkers, aids in better visualization of the cellular function and the follow-up of the molecular process in living organisms without penetrance. Roche Diagnostics, GlaxoSmithKline, Siemens Healthcare, GE Healthcare and Merck & Co are a few of the key players in this market as observed in biomarkers congress. The functional genomics and cytogenetic market is estimated to reach 150M$ by 2017.Functional genomics covers various areas of biomarkers applications like Next gen sequencing, Personalized genome sequencing, Micro RNA sequencing and SNP biomarkers. Cytogenetic biomarkers include Immuno flouscent biomarkers, Molecular imaging biomarkers, Oxidative Stress Biomarkers and si-RNA and mi-RNA.

  • Track 15-1Transcription analysis and profiling
  • Track 15-2Microarray data analysis
  • Track 15-3Molecular biomarkers
  • Track 15-4si-RNA and mi-RNA

The Biomarkers finds its valuable application in the field of Clinical research and development by case study and data management as evident through Biomarker conferences. The Bioethics and intellectual property right establishes the norms and standard of conduct of hypothesis with respect to clinical validation of biomarkers. The incorporation of biomarker in clinical trials for various disease conditions will put forth a valid diagnostic and therapeutic approach utilizing even the medical devices to detect clinical biomarkers. Currently this is the booming industry. Most of the reputed organizations like Pfizer, Parexel and Quintiles are into clinical research and development. The companies, hospitals and clinical research organizations are the hot spots for conducting clinical research with its growth rate increasing exponentially by an estimated  75B$ by 2016.In clinical research and development, clinical biomarkers are used in case study and data management, clinical trials and in medical devices.

  • Track 16-1Clinical biomarkers
  • Track 16-2Medical devices
  • Track 16-3Bioethics and intellectual property rights
  • Track 16-4Biomarkers in Clinical Trials
  • Track 16-5Statistics in clinical studies

Biomarkers play a critical role in disease diagnosis and treatment, especially for the early detection of cancer, to enable screening of asymptomatic populations. Recent omics technologies, such as Transcriptomics, genomics and proteomics approaches besides Metabolomics are accelerating the rate of biomarker discovery. The incorporation of techniques like microarray data analysis, computational biology, data mining methods, Transcriptomics and profiling techniques are playing a crucial role in the validation of biomarkers. Since the Human Genome Project was completed in April 2003, genome-wide association studies (GWAS) have contributed toward a greater understanding of the genetic basis of complex diseases and advances in high-throughput technologies. This has enabled researchers to rapidly map the genome of vertebrates, invertebrates and pathogens through cost-effective methods. The applications of Bioinformatics tool in biomarker research is the current emerging field promoting better diagnosable parameters. The global omics market was valued at nearly $2.8 billion in 2011, nearly $3.2 billion in 2012, and is forecast to grow to nearly $7.5 billion by 2017 after increasing at a compound annual growth rate (CAGR) of 18.7%. The omics technology segment holds the largest share of ~75% of the biomarker discovery market, primarily due to the increase in adoption of proteomics and genomics technologies, globally. There are several approaches in biomarkers discovery and validation like genomics and proteomic approaches, Microarray data analysis, Data mining methods and Transcriptomics and profiling techniques by making use of Computational biology and Application of Bioinformatics in biomarker discovery.

  • Track 17-1Genomic and proteomic approaches
  • Track 17-2Computational biology in biomarker discovery
  • Track 17-3Data mining methods
  • Track 17-4Metabolomics and metabonomics
  • Track 17-5Application of Bioinformatics in Biomarkers Research

Biomarkers of exposure are important in toxicology, because they are an indicator of internal exposure and genetic susceptibility to drug, chemicals or the amount of chemical exposure that got accumulated in the body. Significant advances have been made in developing analytical methods that detect and quantify many natural or synthetic toxins or their breakdown products in the biological matrix. The ability to accurately measure biomarkers of exposure depends upon an adequate understanding of the chemistry and toxicology of the substance under consideration. Epigenetic biomarkers also quantify the degree of exposure to toxic dynamic and pharmacodynamics parameters in pathological and biochemical changes occurring due to exposure to harmful agents, brought to light by toxic dynamics meetings and pharmacodynamics workshops. This emerging field of study is gaining importance in industry with an estimate of more than 7,287 personnel conducting study across the globe. While studying the response and susceptibility parameters like toxic dynamic and pharmacodynamic parameters are taken into consideration to measure the internal exposure and genetic susceptibility to drugs and chemicals.

  • Track 18-1Epigenetic biomarkers
  • Track 18-2Internal exposure and genetic susceptibility to drugs and chemicals
  • Track 18-3Toxicodynamic parameters in pathological and biochemical changes
  • Track 18-4Pharmacodynamic parameters in pathological and biochemical changes

Biomarkers are the characteristic biological measurable indictors for the various disorders if occurring in abnormal levels. These are used as quantitative entities for neurological disorders, genetic disorders, metabolic disorders, cardiac disorders and inborn errors. The present era is focusing on the cancer research utilizing biomarkers as indictor of disease conditions. The lung cancer biomarkers and biomarkers for breast cancer are inclusive of genes, enzymes, proteins and cell surface entitles. Registering a compound annual growth rate of 14.60% from 2011 to 2018, the market for oncology biomarkers was valued at $13.16 billion in 2011 and is expected to be worth $29.78 billion in 2018.Biomarkers are also used in diagnosing and treating various diseases and disorders like Neurological disorders, Genetic disorders, Metabolic disorders, Cardiac disorders, Inborn errors, Lung cancer and Breast cancer.

  • Track 19-1Neurological disorders
  • Track 19-2Genetic disorders
  • Track 19-3Metabolic disorders
  • Track 19-4Cardiac disorders
  • Track 19-5Inborn errors
  • Track 19-6Lung cancer biomarker
  • Track 19-7Biomarkers for breast cancer

Biomarkers are the existing bimolecular and integral indictors of disease condition of biological systems. The techniques used to identify and maximize the expression of biomarkers include RT-PCR genotyping, molecular imaging and dynamics, biochemical  assay and profiling, immunological techniques and chromatographic techniques. A wider approach towards identification of biomarkers lies in the proteomic approach besides utilizing biosensors as a compatible tool for evaluation of biomarker levels in the biological systems. Most of the company’s focus is on generating cost effective durable profiling techniques and equipment to quantify biomarkers within a short span of time. Johnson & Johnson, GlaxoSmithKline Plc., GE Healthcare, Affymetrix Inc., Bio-Rad Laboratories Inc. are a few of the key players in this market. Partnerships, agreements, collaborations, & mergers and acquisitions are the key business strategies adopted by market participants to ensure their growth in the market.

  • Track 20-1RT-PCR genotyping
  • Track 20-2Molecular imaging and dynamics
  • Track 20-3Biochemical assays and profiling
  • Track 20-4Immunological techniques
  • Track 20-5Chromatographic techniques
  • Track 20-6Proteomics for biomarkers
  • Track 20-7Biosensors for Biomarkers detection

Nano science is the study of structures and materials on the scale of nanometres. Nanotechnology may be able to create many new materials and devices with a vast range of applications in medicine, electronics, biomaterials energy production, and consumer products. Nanotechnology is evolving rapidly with nanoparticles events.  An estimated 1 million workers in R&D and production are involved in the field of Nano science and nanomaterial generation. Interaction of biomarkers with nanoparticles aids in identification and validation through biological and biomedical applications. Current market holds Nano devices and nanomaterial for identification, quantifying, calibrating and even in surgeries. The US leads the world in investing and in the number of Nanotech Companies. Global consumption of nanomaterial is expected to grow in unit terms from nearly 225,060 metric tons in 2014 to nearly 584,984 metric tons in 2019, a compound annual growth rate (CAGR) of 21.1% for the period of 2014 to 2019.Nano science is another rapidly growing area where application of nanotechnology to biomarkers is used for biological and biomedical applications like Nano devices.

  • Track 21-1Biological and biomedical applications
  • Track 21-2Nanodevices
  • Track 21-3Interactions of biomarkers with nanoparticles
  • Track 21-4Nanomaterial for biomarker identificaion
  • Track 21-5Application of nanotechnology to biomarkers

Biomarkers are used for detecting kidney toxicity. Kidney toxicity is detected using biomarkers serum creatinine and blood urea nitrogen. Many qualified biomarkers are used to develop products to conquer the kidney toxicity problem. Latest research on biomarkers discovered new approaches to predicting and recognising toxic exposures of macromolecular adducts and their potential consequences.

  • Track 22-1Reproductive and developmental toxicity
  • Track 22-2Pulmonary toxicity, hepatotoxicity and nephrotoxicity
  • Track 22-3Immunotoxicity and autoimmune diseases
  • Track 22-4Toxicity biomarkers
  • Track 22-5Biomarkers of radiation
  • Track 22-6Pharmaceuticals and neutraceuticals biomarkers

Biomarkers can be used for microbial infections and can be used for early diagnosis and prognosis of the disease. The diagnostic performance of biomarkers is usually measured in terms of sensitivity.

  • Track 23-1Viral infections
  • Track 23-2Pathogenic infections
  • Track 23-3Bacterial infections
  • Track 23-4Sepsis biomarkers

The role of Biomarkers in drug discovery and development is to understand the pathophysiology of disease. Biomarkers can be a clinical tool for drug discovery and development by confirming the efficacy and safety to the right patient. Biomarkers can be used in understanding the mechanism of drug. 

  • Track 24-1Applications in new drug development
  • Track 24-2Translational medicine
  • Track 24-3Clinical trials, pharmacokinetics and pharmacodynamics
  • Track 24-4Commercializing biomarkers in therapeutic and diagnostic application

Recently there has been enhanced and advanced biomedical technology such as high-throughput molecular imaging and microarrays to monitor SNPs, gene and protein expressions, to provide exhaustive situations for individuals. The biological and medical status from such data sets, which are viewed as biomarkers in a wide sense to help to do identification, association, and prediction studies for phenotypes such as cancer subtypes, prognosis, treatment responsiveness, and adverse reactions for personalized medicine.

  • Track 25-1Molecular profiling technologies
  • Track 25-2Perspectives on integrated approach to biomarkers
  • Track 25-3Urological cancer biomarkers
  • Track 25-4Cardiovascular biomarkers

A nutritional biomarker can be any biological specimen that is an indicator of nutritional status with respect to intake or metabolism of dietary constituents. It can be a biochemical, functional or clinical index of status of an essential nutrient or other dietary constituent. Nutritional biomarkers may be interpreted more broadly as a biologic consequence of dietary intake or dietary patterns.

  • Track 26-1Biomarkers and dietary assessment
  • Track 26-2Nutritional biomarkers and inflammation
  • Track 26-3Nutritional biomarkers and kidney function
  • Track 26-4Nutritional biomarkers and neurological diseases

Current Research Concepts in Biomarkers include research in glucose disorders, Biomarkers in disease and health, technologies in biomarker discovery, translational biomarker research and the use of biomarkers in pre-clinical and clinical studies.

  • Track 27-1Biomarker research in glucose disorders
  • Track 27-2Biomarkers and new therapeutic strategies
  • Track 27-3New concepts and emerging technologies of biomarkers research
  • Track 27-4Applications of biomarkers in vaccines

An oncologist is a doctor who specializes in treating people with cancer. The oncologist’s research into the causes, prevention, detection, and treatment of cancer is going on in many medical centres throughout the world.

  • Track 28-1Biomarker specialists
  • Track 28-2Oncology biomarker Specialists
  • Track 28-3Biomarker specialists career

With the emerging importance to quantify and validate various disease conditions, many organizations, companies, and universities have stepped forward to contribute to the field of biomarkers discovery and quantification for better prognosis of disease conditions. The Biomarkers is the second leading industry after clinical research and development. The Biomarkers in pharmaceutical industry, biomarkers in oncology & other diseases has attained utmost recognition due to global spread of cancer and other diseases. The Biomarkers validation and regulatory affairs and diagnostic biomarker are booming industry with an estimate of more than 270 companies involved across the globe in 2016.

  • Track 29-1World biomarkers market
  • Track 29-2Biomarkers market Analysis
  • Track 29-3Cancer biomarker market

Biomarkers case reports play a crucial role in moving new treatments to patients who need those most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice.

  • Track 30-1Diagnostic and prognostic biomarkers
  • Track 30-2Medical and workplace applications
  • Track 30-3Alcohol biomarkers

A key ingredient in successful entrepreneurship is self-knowledge. Biomarkers-2016 aims to bring together all existing and budding bio entrepreneurs to share experiences and present new innovations and challenges in cancer community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Cancer science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. This three day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from Biomarkers to signalling pathways to novel therapeutic approaches to the scientific hub. In addition to our outstanding speakers, we will also showcase short talks and poster presentations from submitted abstracts .The speakers will discuss state-of-the-art treatments, current guidelines, clinical challenges, and review recent trial data and emerging therapeutic approaches with the potential to impact clinical practice. This session will include combined efforts of World-renowned speakers, the most recent techniques, developments, and the newest updates in Biomarkers.